Together, these findings highlight an important role for CAF-derived CXCL12 during tumor progression and chemoresistance, and indicate that inhibition of the CXCL12/CXCR4 signaling axis may chemo-sensitize prostate cancer cells. Here, CXCR4 is linked to neoplasm.